ClinicalTrials.gg
Active, not recruitingNCT06018337Updated Sep 24, 2026

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

A Phase 3 interventional study of DB-1303/BNT323 and Capecitabine in Metastatic Breast Cancer, sponsored by DualityBio Inc.. Active, not recruiting at 258 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by DualityBio Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
541
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
204th of 1,519
541 · median 120
Started
2024
with 221 others
Phase 3
331 of 1,928
120 open now
Primary completion
2026-08
later than 443 of 1,063 live
Registered
1,170th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 204th largest by enrollment of the 1,519 interventional ones that give a count, is one of 222 that started in 2024, is one of 331 in phase 3, reaches primary completion later than 443 of the 1,063 other live ones, and was the 1,170th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry [IHC]2+/in situ hybridization [ISH]- and IHC 1+) population.

Read the detailed description

The study is a Phase III, Randomized, Multi-center, Open-label study in HER2-low, HR+ metastatic breast cancer subjects whose disease has progressed on at least 2 lines of prior ET or within 6 months of first line ET + Cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting. The primary purpose of the study is to determine the efficacy and safety of DB-1303/BNT323 compared with investigator's choice single agent chemotherapy in the target population. Approximately 532 subjects with HER2 IHC 2+/ISH- and IHC 1+ (HER2-low] expression will be randomized 1:1 across approximately 255 centers globally to receive either DB-1303 or investigator's choice single agent chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) until Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • HER2-low
  • IHC 2+
  • BC
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of ).

2. documented breast cancer that:

  1. Is advanced or
  2. Has -low expression (IHC 1+ or IHC 2+/ISH-) as determined by the central laboratory result.
  3. Was never previously reported as HER2-positive (IHC 3+ or ISH+) as per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
  4. Is documented as HR+ (either estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR ≥1%]) per ASCO/CAP guidelines (Allison et al 2020).

3. Must have an adequate tumor tissue sample available for assessment of HER2 by central laboratory, in formalin fixation and paraffin embedding (FFPE) blocks based on a mandatory FFPE tumor sample preferably obtained at the time of metastatic disease or later;

4. performance status of 0 or 1.

5. Must have had either:

  1. Disease progression on endocrine therapy + CDK4/6 inhibitor within 6 months of starting treatment for metastatic disease and considered appropriate for chemotherapy as the next treatment by the investigator, OR
  2. Disease progression on at least 2 previous lines of ET with or without a targeted therapy (such as CDK4/6, mammalian target of rapamycin [mTOR] or phosphoinositide 3-kinase [PI3-K] inhibitors) administered for the treatment of metastatic disease.

6. No prior chemotherapy for advanced or metastatic breast cancer. Subjects who have received chemotherapy in the or adjuvant setting are eligible, as long as they have had a disease-free interval (defined as completion of systemic chemotherapy to diagnosis of advanced or metastatic disease) of >12 months.

7. ≥12 weeks at screening.

8. Subjects must have at least one as defined per v1.1 (For bone only disease, subjects with lytic or mixed lytic bone lesions that can be measured by CT or MRI are eligible; subjects with sclerotic/osteoblastic bone lesions are not eligible).

9. Has ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before randomization.

10. Adequate organ and bone marrow function within 14 days before randomization.

11. Has adequate treatment before randomization.

12. Evidence of status or negative serum pregnancy test for females of who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of study treatment.

Women of childbearing potential are defined as those who are not surgically sterile (i.e., underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.

13. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of from the time of screening and must agree to continue using such precautions for 7 months after the last dose of study treatment. Not all methods of contraception are highly effective. Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the subject for the duration of the study treatment and the drug washout period (7 months). Periodic abstinence (e.g., calendar ovulation, symptothermal, post ovulation methods), the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female subjects must not donate ova, or retrieve for their own use, from the time of screening and throughout the study treatment period, and for at least 7 months after the last dose of study treatment. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to randomization in this study.

14. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening and throughout the duration of the study treatment and the washout period (4 months after the last dose of DB-1303, 6 months after the last dose of paclitaxel or nab-paclitaxel, and 3 months after the last dose of capecitabine). Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the subject for the duration of the study treatment and the drug washout period. Periodic abstinence (e.g., calendar ovulation, symptothermal, post ovulation methods), the rhythm method, and the withdrawal method are not acceptable methods of contraception. It is strongly recommended for the female partners of a male subject also use at least one highly effective method of contraception throughout this period. In addition, male subjects should refrain from fathering a child or donating sperm throughout the duration of the study and the washout period (4 months after the last dose of DB-1303, 6 months after the last dose of paclitaxel or nab paclitaxel, and 3 months after the last dose of capecitabine). Preservation of sperm should be considered prior to randomization in this study.

15. Must be able and willing to comply with the protocol requirements and must sign and date the informed consent form prior to any screening evaluations.

Exclusion criteria

Exclusion Criteria:

  1. Ineligible for all options in the investigator's choice chemotherapy arm.
  2. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events or compromise the ability of the subject to give written .
  3. Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring repeated drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the randomization.
  4. Uncontrolled or significant cardiovascular disease
  5. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis which needs and antibiotics) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
  6. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline or Grade ≤ 2 anemia.
  7. Previous treatment with anti- therapy.
  8. Prior treatment with antibody-drug conjugate that comprised an exatecan derivative that is a topoisomerase I inhibitor.
  9. Prior randomization or treatment in a previous DB-1303/BNT323 study regardless of treatment assignment.
  10. Has substance abuse or any other medical conditions such as psychological conditions, that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
  11. Individuals who are dependent on the Sponsor, clinical site, or Investigator (e.g., is an employee of the Sponsor or the clinical trial site, a dependent of the Investigator, or any site staff member otherwise supervised by the Investigator).
  12. Individuals who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities, in accordance with local regulations.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
541 participants (actual)

Study arms

  • Experimental
    DB-1303/BNT323

    Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W

    Drug: DB-1303/BNT323

  • Active comparator
    investigator's choice single agent chemotherapy

    Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles; paclitaxel:80 mg/m2, IV, Every week (QW) in 3-week cycles; or nab-paclitaxel: 100 mg/m2, IV, Every week (QW) for 3 weeks followed by a one-week rest period in 4-week cycles) until RECIST 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.

    Drug: Capecitabine · Drug: Paclitaxel · Drug: Nab-paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) in the HR+, HER2-low population

    PFS by BICR according to RECIST 1.1 in the HR+, HER2-low population

    Time frame: Up to approximately 51 months

Secondary outcomes

  1. Overall survival (OS) in the HR+, HER2-low population

    OS in the HR+, HER2-low population

    Time frame: Up to approximately 51 months

  2. Objective response rate (ORR) in the HR+, HER2-low population

    ORR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population

    Time frame: Up to approximately 51 months

  3. PFS by Investigator assessment

    PFS by Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population

    Time frame: Up to approximately 51 months

  4. Duration of response (DoR) in the HR+, HER2-low population

    DoR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population

    Time frame: Up to approximately 51 months

  5. Treatment-emergent adverse events (TEAEs)

    TEAEs per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: from the time of the subject signing the informed consent form (ICF) until the follow-up period is completed (35 days after the last dose of study treatment

  6. Serious adverse events (SAEs)

    SAEs per NCI CTCAE v5.0

    Time frame: from the time of the subject signing the ICF until the follow-up period is completed (35 days after the last dose of study treatment

  7. Patient reported outcomes (PROs): European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - C30

    Change from baseline in the functioning/symptom/global quality of life (QoL) subscales of EORTC QLQ-C30. Scale scores range from 0-100. For functioning and global QoL scales, higher scores indicate better functioning or global health status. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Up to approximately 51 months

  8. Patient reported outcomes (PROs): EORTC QLQ-BR45

    Change from baseline in the functioning/symptom subscales of EORTC QLQ-BR45. Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Up to approximately 51 months

  9. Patient reported outcomes (PROs): European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)

    Change from baseline in EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. VAS score range from 0-100, higher scores indicate better health status.

    Time frame: Up to approximately 51 months

  10. European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)

    EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. The change from baseline value will be reported.

    Time frame: Up to approximately 51 months

07

Study locations

258 sites
  • Research Site 1141-0
    Tucson, Arizona 85704, United States
  • Research Site 1114-0
    Fullerton, California 92835, United States
  • Research Site 1107-0
    Los Angeles, California 90095, United States
  • Research Site 1118-0
    Orange, California 92868-3201, United States
  • Research Site 1143-0
    Sacramento, California 95814, United States
  • Research Site 1132-0
    Santa Barbara, California 93105, United States
  • Research Site 1137-0
    Aurora, Colorado 80045, United States
  • Research Site 1129-0
    Lone Tree, Colorado 80124, United States
  • Research Site 1154-0
    Jacksonville, Florida 32256, United States
  • Research Site 1145-0
    Miami, Florida 33136, United States
  • Research Site 1150-0
    Orange City, Florida 32763, United States
  • Research Site 1125-0
    Palm Bay, Florida 32909, United States
  • Research Site 1155-0
    Athens, Georgia 30607, United States
  • Research Site 1110-0
    Savannah, Georgia 31405, United States
  • Research Site 1147-0
    Chicago, Illinois 60611, United States
  • Research Site 1124-0
    Chicago Ridge, Illinois 60415, United States
  • Research Site 1152-0
    Fort Wayne, Indiana 46804, United States
  • Research Site 1106-0
    Merriam, Kansas 66204, United States
  • Research Site 1104-0
    Louisville, Kentucky 40202, United States
  • Research Site 1122-0
    Silver Spring, Maryland 20904, United States
  • Research Site 1109-0
    Kansas City, Missouri 64111, United States
  • Research Site 1158-0
    Camden, New Jersey 08103, United States
  • Research Site 1111-0
    Florham Park, New Jersey 07932, United States
  • Research Site 1157-0
    Sante Fe, New Mexico 87505, United States
  • Research Site 1148-0
    Staten Island, New York 10314, United States
  • Research Site 1105-0
    Westbury, New York 11590, United States
  • Research Site 1144-0
    Chapel Hil, North Carolina 27599, United States
  • Research Site 1138-0
    Akron, Ohio 44305, United States
  • Research Site 1160-0
    Cincinnati, Ohio 45220, United States
  • Research Site 1133-0
    Eugene, Oregon 97401-8122, United States
  • Research Site 1126-0
    Tigard, Oregon 97223, United States
  • Research Site 1134-0
    Broomall, Pennsylvania 19008, United States
  • Research Site 1123-0
    Horsham, Pennsylvania 19044, United States
  • Research Site 1149-0
    Knoxville, Tennessee 37909, United States
  • Research Site 1102-0
    Nashville, Tennessee 37203, United States
  • Research Site 1159-0
    Nashville, Tennessee 37203, United States
  • Research Site 1101-0
    Dallas, Texas 75246, United States
  • Research Site 1116-0
    Denison, Texas 75020, United States
  • Research Site 1115-0
    Houston, Texas 77030, United States
  • Research Site 1117-0
    San Antonio, Texas 78240, United States
  • Research Site 1130-0
    Salt Lake City, Utah 84124, United States
  • Research Site 1108-0
    Fairfax, Virginia 22031, United States
  • Research Site 1131-0
    Fairfax, Virginia 22031, United States
  • Research Site 1127-0
    Roanake, Virginia 24014, United States
  • Research Site 5411-0
    Bahía Blanca, Buenos Aires B8001HXM, Argentina
  • Research Site 5414-0
    CABA, Buenos Aires C1015ABO, Argentina
  • Research Site 5405-0
    La Plata, Buenos Aires B1902CMJ, Argentina
  • Research Site 5413-0
    Mar del Plata, Buenos Aires 7600, Argentina
  • Research Site 5408-0
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Research Site 5403-0
    CABA, Ciudad Autonoma Buenos Aires C1426ANZ, Argentina
  • Research Site 5407-0
    Ciudad Autonoma Buenos Aires, Ciudad Autonoma Buenos Aires 1431, Argentina
  • Research Site 5409-0
    Ciudad Autonoma Buenos Aires, Ciudad Autonoma Buenos Aires C1280AEB, Argentina
  • Research Site 5412-0
    Córdoba, Córdoba Province X5008HHW, Argentina
  • Research Site 5402-0
    Viedma, Río Negro Province R8500ACE, Argentina
  • Research Site 5401-0
    Rosario, Santa Fe Province 2000, Argentina
  • Research Site 5406-0
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Research Site 5404-0
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Research Site 6108-0
    Camperdown, New South Wales 2050, Australia
  • Research Site 6116-0
    Kingswood, New South Wales 2747, Australia
  • Research Site 6109-0
    Liverpool, New South Wales 2170, Australia
  • Research Site 6102-0
    Sydney, New South Wales 2109, Australia
  • Research Site 6106-0
    Birtinya, Queensland 4575, Australia
  • Research Site 6101-0
    South Brisbane, Queensland 4101, Australia
  • Research Site 6107-0
    Southport, Queensland 4215, Australia
  • Research Site 6104-0
    Townsville, Queensland 4814, Australia
  • Research Site 6110-0
    Adelaide, South Australia 2155, Australia
  • Research Site 6103-0
    Bendigo, Victoria 3550, Australia
  • Research Site 6105-0
    St Albans, Victoria 3021, Australia
  • Research Site 6113-0
    Traralgon, Victoria 3844, Australia
  • Research Site 6114-0
    Perth, Western Australia 6009, Australia
  • Research Site 3201-0
    Brussels, Brussels Capital 1200, Belgium
  • Research Site 3204-0
    Ghent, Gent 9000, Belgium
  • Research Site 3205-0
    Jette, Jette 1090, Belgium
  • Research Site 3203-0
    Leuven, Leuven 3000, Belgium
  • Research Site 3207-0
    Liège, Liege 4000, Belgium
  • Research Site 3202-0
    Roeselare, Roeselare 8800, Belgium
  • Research Site 1007-0
    Winnipeg, Manitoba R3E 0V9, Canada
  • Research Site 1003-0
    Brampton, Ontario L6R 3J7, Canada
  • Research Site 1001-0
    Toronto, Ontario M2K 1E1, Canada
  • Research Site 1004-0
    Montreal, Quebec H3T 1E2, Canada
  • Research Site 1005-0
    Montreal, Quebec H3T 1M5, Canada
  • Research Site 1006-0
    Montreal, Quebec H4A 3J1, Canada
  • Research Site 1002-0
    Sherbrooke, Quebec J1H5N4, Canada
  • Research Site 8639-0
    Bengbu, Anhui 233004, China
  • Research Site 8640-0
    Hefei, Anhui 230088, China
  • Research Site 8614-0
    Hefei, Anhui 230601, China
  • Research Site 8601-0
    Beijing, Beijing Municipality 100021, China
  • Research Site 8625-0
    Beijing, Beijing Municipality 100071, China
  • Research Site 8653-0
    Beijing, Beijing Municipality 100142, China
  • Research Site 8627-0
    Chongqing, Chongqing Municipality 400030, China
  • Research Site 8651-0
    Fuzhou, Fujian 350015, China
  • Research Site 8638-0
    Xiamen, Fujian 361003, China
  • Research Site 8630-0
    Lanzhou, Gansu 730000, China
  • Research Site 8604-0
    Guangzhou, Guangdong 510000, China
  • Research Site 8628-0
    Guangzhou, Guangdong 510060, China
  • Research Site 8621-0
    Huizhou, Guangdong 516003, China
  • Research Site 8622-0
    Zhuhai, Guangdong 519000, China
  • Research Site 8615-0
    Nanning, Guangxi 530021, China
  • Research Site 8629-0
    Baoding, Hebei 071030, China
  • Research Site 8645-0
    Shijiazhuang, Hebei 50011, China

Showing the first 100 of 258 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Aug 2026, 30 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 30 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Aug 30, 2023
StartActual
Jan 18, 2024
Primary completionActual
Aug 12, 2026
CompletionEst.
Aug 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06018337
Lead sponsor
DualityBio Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Jan 18, 2024
Primary completion
Aug 12, 2026
Completion
Aug 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Joyce O'Shaughnessy, PHD
principal investigator · Texas Oncology - Baylor Charles A. Sammons Cancer center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab pamirtecan

Start the discussion